109.92

0.90% -0.9443

Sarepta Therapeutics Inc (SRPT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SRPT Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$110.86

Aprire:

$110.87

Volume 24 ore:

185.61K

Relative Volume:

0.22

Capitalizzazione di mercato:

$10.51B

Reddito:

$1.50B

Utile/perdita netta:

$47.30M

Rapporto P/E:

-14.04

EPS:

-7.83

Flusso di cassa netto:

$-527.92M

1 W Prestazione:

+0.69%

1M Prestazione:

-13.71%

6M Prestazione:

-14.92%

1 anno Prestazione:

+30.66%

Intervallo 1D:

$109.03

$111.78

Intervallo di 1 settimana:

$102.16

$111.78

Portata 52W:

$78.67

$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Nome

Sarepta Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

617-274-4000

Indirizzo

215 FIRST STREET, CAMBRIDGE, MA

Dipendente

1,314

Cinguettio

@sarepta

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

SRPT's Discussions on Twitter

Confronta SRPT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SRPT	109.91	10.51B	1.50B	47.30M	-527.92M	-7.83
VRTX	446.52	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.51	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.70	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	250.25	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.17	24.49B	3.30B	-501.07M	1.03B	11.54

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-31	Iniziato	BMO Capital Markets	Outperform
2023-12-13	Ripresa	Citigroup	Buy
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-11-21	Iniziato	Wedbush	Outperform
2023-10-31	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-31	Downgrade	Oppenheimer	Outperform → Perform
2023-06-23	Downgrade	Evercore ISI	Outperform → In-line
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-04	Iniziato	Citigroup	Buy
2023-03-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-12-22	Reiterato	BTIG Research	Buy
2022-12-16	Aggiornamento	UBS	Neutral → Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2022-01-05	Reiterato	Needham	Buy
2021-12-09	Aggiornamento	Oppenheimer	Perform → Outperform
2021-11-05	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-15	Aggiornamento	Guggenheim	Neutral → Buy
2021-08-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-06-15	Iniziato	BTIG Research	Buy
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-01-12	Downgrade	Citigroup	Buy → Neutral
2021-01-11	Downgrade	UBS	Buy → Neutral
2021-01-08	Downgrade	JP Morgan	Overweight → Underweight
2021-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-01-08	Downgrade	Raymond James	Outperform → Mkt Perform
2020-11-11	Iniziato	Berenberg	Hold
2020-10-28	Iniziato	UBS	Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-08-20	Downgrade	Credit Suisse	Outperform → Neutral
2020-03-31	Iniziato	Mizuho	Buy
2019-11-01	Iniziato	Guggenheim	Buy
2019-08-21	Reiterato	Needham	Buy
2019-07-09	Reiterato	Morgan Stanley	Overweight
2019-07-01	Reiterato	RBC Capital Mkts	Outperform
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-11	Reiterato	Credit Suisse	Outperform
2018-10-12	Iniziato	Bernstein	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-09-26	Reiterato	RBC Capital Mkts	Outperform
2018-09-14	Ripresa	BofA/Merrill	Buy
2018-09-06	Iniziato	Credit Suisse	Outperform
2018-08-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-06-21	Reiterato	Robert W. Baird	Outperform
2018-06-20	Reiterato	Needham	Buy
2018-06-19	Reiterato	H.C. Wainwright	Buy

Mostra tutto

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

Nov 20, 2024

SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program - MSN

Nov 20, 2024

S&P 500 Futures Climb in Premarket Trading; Target, Fabrinet Lag - Barron's

Nov 20, 2024

Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN

Nov 20, 2024

Sarepta upgraded at Cantor on pipeline, growth potential - MSN

Nov 20, 2024

Sarepta Therapeutics (NASDAQ:SRPT) Cut to Hold at StockNews.com - MarketBeat

Nov 20, 2024

Nov 18, 2024

Braun Stacey Associates Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 18, 2024

Thrivent Financial for Lutherans Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - Yahoo Finance

Nov 18, 2024

Nov 17, 2024

Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) - MSN

Nov 17, 2024

Aigen Investment Management LP Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 17, 2024

Nov 16, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Mizuho Markets Americas LLC - MarketBeat

Nov 16, 2024

Nov 15, 2024